The Delivery Vehicle That Is Harder to Make Than the Drug
Cell and gene therapies are among the most transformative medical innovations in the current pharmaceutical pipeline, offering the potential to correct the genetic defects underlying hereditary diseases with a single treatment whose durability in patients stems from the permanent modification of cells that eliminates the recurring dosing requirement of conventional pharmaceuticals. Luxturna, the first FDA-approved gene therapy for a genetic disease, restores functional vision in patients with inherited retinal dystrophy caused by mutations in the RPE65 gene through a single bilateral injection of a recombinant adeno-associated virus vector carrying a functional copy of the RPE65 gene. Zolgensma, the most expensive medicine ever approved at two million dollars per dose, treats spinal muscular atrophy with a single infusion of an AAV9 vector carrying the SMN1 gene whose absence causes the progressive motor neuron degeneration that SMA creates. The clinical success of these therapies and the expanding pipeline of gene therapy programmes targeting diseases from haemophilia to Duchenne muscular dystrophy to sickle cell disease reflects the maturation of gene therapy from a research concept into a pharmaceutical category whose commercial launch has been achieved and whose pipeline expansion is accelerating.
The manufacturing challenge that viral vector production presents is the single most commercially significant constraint on the pace at which cell and gene therapy can reach the patients whose diseases they could transform. An adeno-associated virus vector is a biological macromolecular complex whose production requires the transient transfection of mammalian cells with plasmid DNA encoding the AAV capsid proteins and the therapeutic gene, followed by the cell culture whose duration allows AAV particle assembly, the cell lysis or harvest step that releases the assembled particles, and the extensive downstream purification process whose multiple chromatography and filtration steps remove empty capsids, cellular debris, plasmid DNA, and process-related impurities to achieve the purity and potency specifications that regulatory authorities require for clinical or commercial use. The process is inherently lower productivity than the microbial fermentation or mammalian cell culture that conventional pharmaceutical biologics use, because AAV particles are produced at lower titres per litre of cell culture than antibody proteins, because the biological complexity of AAV particle assembly creates greater process variability than antibody secretion, and because the analytical methods required to characterise AAV product quality, including the ratio of full to empty capsids and the purity of the vector genome, are more technically demanding than the antibody product quality measurements that pharmaceutical analytical development has decades of experience with.
The CDMO Capacity Race
The commercial response to viral vector manufacturing capacity constraints has been a race among contract development and manufacturing organisations to invest in the bioreactor capacity, cleanroom infrastructure, and technical expertise that cell and gene therapy developers whose own manufacturing capabilities are insufficient for commercial-scale production need to access through outsourcing. Lonza's gene therapy CDMO business, whose investment in AAV and lentiviral vector manufacturing at its facilities in Houston, Texas and Geleen, Netherlands has been one of the largest single CDMO capital investments in the viral vector manufacturing sector, creates the large-scale viral vector contract manufacturing capability that multiple commercial gene therapy programmes depend on for their approved product supply. Lonza's established position as a preferred CDMO partner for the first commercial AAV gene therapies including Luxturna's manufacturing reflects both the technical capability and the regulatory track record that commercial gene therapy product manufacturing requires from its CDMO suppliers.
Oxford Biomedica, the UK company whose lentiviral vector manufacturing expertise was developed during its work on its own clinical-stage gene therapy programmes, has expanded its CDMO business substantially as the demand for lentiviral vector manufacturing capacity for CAR-T cell therapy production has grown with the commercial success of axicabtagene ciloleucel and tisagenlecleucel. Its Oxford facility expansion and its acquisition by Homology Medicines' parent company create the lentiviral vector CDMO capacity that the CAR-T cell therapy manufacturing surge is absorbing. Spark Therapeutics' in-house manufacturing capability for Luxturna's AAV2 vector represents the fully integrated gene therapy company model where manufacturing is developed in-house rather than outsourced, creating the production control that the commercial supply of a two million dollar per dose product requires but also the capital investment and technical risk that most gene therapy developers cannot sustain before their products achieve commercial revenue.
Manufacturing Innovation and Productivity Improvement
The viral vector manufacturing industry's productivity improvement efforts focus on the upstream bioreactor process intensification whose cell density and AAV titre improvement creates more vector product per litre of manufacturing capacity, and the downstream purification process optimisation whose step yield improvements and process robustness reduce the product loss and batch failure rates that current manufacturing processes suffer from. The transition from adherent cell culture in multilayer flasks to suspension cell culture in bioreactors, which allows manufacturing scale-up through bioreactor volume increase rather than the linear addition of flask surface area whose labour requirement does not scale efficiently, is the manufacturing platform shift that the viral vector industry is implementing across its manufacturing base to improve scalability and cost of goods.
Top 10 Companies in Viral Vector Manufacturing Globally
- Lonza: Swiss CDMO with the largest commercial viral vector manufacturing capacity including AAV and lentiviral vector production; its Houston and Geleen facilities and its partnerships with multiple commercial gene therapy programmes create the viral vector CDMO that the cell and gene therapy industry's commercial manufacturing outsourcing most substantially depends on.
- Oxford Biomedica: UK lentiviral vector CDMO with expanded manufacturing capacity for CAR-T cell therapy and gene therapy programmes; its lentiviral vector manufacturing expertise and its facility expansion create the established UK gene therapy contract manufacturer whose lentiviral capability serves the CAR-T commercial manufacturing demand.
- Spark Therapeutics (Roche): US gene therapy company with in-house AAV manufacturing for Luxturna and its pipeline; its commercial AAV manufacturing track record and its Roche parent's resources create the integrated gene therapy company whose manufacturing capability is the reference standard for commercial AAV gene therapy product supply.
- Catalent Gene Therapy: US CDMO with AAV and lentiviral vector manufacturing at its Harmans, Maryland facility; its viral vector manufacturing services and its integration within Catalent's comprehensive pharmaceutical CDMO business create the large-scale pharmaceutical CDMO's gene therapy manufacturing offering whose breadth of service from drug substance through finished product differentiates it from specialist viral vector CDMOs.
- Thermo Fisher Scientific (Brammer Bio): US life sciences company with gene therapy viral vector manufacturing through its Brammer Bio acquisition; its viral vector manufacturing facilities and its analytical services create the instrument and CDMO combination business whose integration within Thermo Fisher's broader life science ecosystem creates the gene therapy supply chain infrastructure.
- Genezen: US gene therapy CDMO with AAV vector manufacturing and analytical development services; its focus on clinical-stage gene therapy development programmes whose manufacturing needs differ from commercial-scale production creates the CDMO position that serves the development pipeline whose growth creates the future commercial manufacturing demand.
- Vigene Biosciences: US viral vector manufacturing and gene delivery company with research and GMP-grade AAV and lentiviral vector production; its accessible pricing and its research-to-GMP manufacturing continuum create the viral vector supplier that academic and emerging biotechnology gene therapy programmes use for their pre-clinical and early clinical supply needs.
- Genezen (BioReliance/Merck): Merck's gene therapy viral vector manufacturing services operating under the BioReliance brand; its integration within Merck's global CDMO network and its viral vector manufacturing capability create the large pharmaceutical company's gene therapy manufacturing services offering whose regulatory track record and financial backing serve the risk-averse pharmaceutical company gene therapy programmes.
- Batavia Biosciences: Dutch viral vector CDMO with AAV and other vector manufacturing for gene therapy development and commercial programmes; its European location and its regulatory compliance with both FDA and EMA requirements create the European viral vector CDMO that gene therapy developers targeting both US and European regulatory pathways use for their manufacturing development.
- National Resilience: US advanced manufacturing company with gene therapy manufacturing capability as part of its biopharmaceutical CDMO business; its biodefense heritage and its investment in advanced manufacturing infrastructure create the manufacturing capability for complex biologics including viral vectors whose strategic importance to both commercial gene therapy and national biodefense programmes justifies its government-supported investment model.